Patient eligibility
A total of 83 children and adolescents with a malignant disease underwent allogeneic hematopoietic cell transplantation (allo-HCT) after MAC with TBI at Sapporo Hokuyu Hospital between October 1994 and July 2018. All of the patients were enrolled in this study, and their clinical data were retrospectively evaluated by December 31st, 2019. All enrolled patients were < 20 years old, and their diagnoses of hematologic malignancies were: acute lymphoblastic leukemia, acute myeloid leukemia, chronic myeloid leukemia, juvenile myelomonocytic leukemia, myelodysplastic syndromes, and non-Hodgkin lymphoma. Additionally, the diagnoses for solid tumors included neuroblastoma and hepatoblastoma. Ninety-two percent of the diagnoses were hematologic malignant disease. The enrolled patients received HCT from related or unrelated donors at either complete remission or incomplete remission.
This study was conducted according to the Declaration of Helsinki and was approved by the Ethics Committee at Sapporo Hokuyu Hospital, Sapporo, Japan.